organization · Reporting owner

HealthCap VII GP S.A.

Disclosed activity across 2 companies

Tapewire entity: 148047
SEC CIK: 0001790047

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aprea Therapeutics, Inc.APRE · Entity 7948	10% owner	October 07, 2019	October 07, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aprea Therapeutics, Inc.

Report date October 07, 2019 · Filed October 07, 2019

Jointly reported with HealthCap VII, L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	2,366,104	Last balance in matching sequence After 2019-10-07 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2019-10-07 · Conversion · Acquired 1,661,382 · Balance 1,671,941 F1: Immediately prior the closing of the Issuer's initial public offering the shares of preferred stock automatically converted into shares of the common stock. Each share of preferred stock was convertible into shares of common stock at any time at the option of the holder and had no expiration date. F2: The securities are directly held by HealthCap VII L.P. (the "Fund"). HealthCap VII GP S.A. (the "General Partner") is the sole general partner of the Fund. The General Partner disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Row 2 · 2019-10-07 · Conversion · Acquired 427,496 · Balance 2,099,437 F1: Immediately prior the closing of the Issuer's initial public offering the shares of preferred stock automatically converted into shares of the common stock. Each share of preferred stock was convertible into shares of common stock at any time at the option of the holder and had no expiration date. F2: The securities are directly held by HealthCap VII L.P. (the "Fund"). HealthCap VII GP S.A. (the "General Partner") is the sole general partner of the Fund. The General Partner disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Row 3 · 2019-10-07 · Purchase · Acquired 266,667 · Balance 2,366,104 F2: The securities are directly held by HealthCap VII L.P. (the "Fund"). HealthCap VII GP S.A. (the "General Partner") is the sole general partner of the Fund. The General Partner disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2019-10-07 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-10-07 · Conversion · Disposed 1,661,382 · Balance 0 F1: Immediately prior the closing of the Issuer's initial public offering the shares of preferred stock automatically converted into shares of the common stock. Each share of preferred stock was convertible into shares of common stock at any time at the option of the holder and had no expiration date. F2: The securities are directly held by HealthCap VII L.P. (the "Fund"). HealthCap VII GP S.A. (the "General Partner") is the sole general partner of the Fund. The General Partner disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
Series C Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2019-10-07 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-10-07 · Conversion · Disposed 427,496 · Balance 0 F1: Immediately prior the closing of the Issuer's initial public offering the shares of preferred stock automatically converted into shares of the common stock. Each share of preferred stock was convertible into shares of common stock at any time at the option of the holder and had no expiration date. F2: The securities are directly held by HealthCap VII L.P. (the "Fund"). HealthCap VII GP S.A. (the "General Partner") is the sole general partner of the Fund. The General Partner disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

Filing footnotes · ownership attribution and instrument terms

F1: Immediately prior the closing of the Issuer's initial public offering the shares of preferred stock automatically converted into shares of the common stock. Each share of preferred stock was convertible into shares of common stock at any time at the option of the holder and had no expiration date.

F2: The securities are directly held by HealthCap VII L.P. (the "Fund"). HealthCap VII GP S.A. (the "General Partner") is the sole general partner of the Fund. The General Partner disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Fusion Pharmaceuticals Inc.

Report date June 30, 2020 · Filed July 02, 2020

Jointly reported with HealthCap VII, L.P.

Section 16 reporting ended · disclosed 2020-07-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	IndirectSee Footnote	3,807,247	Last balance in matching sequence After 2020-06-30 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2020-06-30 · Conversion · Acquired 2,497,345 · Balance 2,497,345 F1: Represents Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemable into Class A Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class A Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis. F2: The securities are directly held by HealthCap VII, L.P. ("HCLP"). HealthCap VII GP SA ("HCSA") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. Johan Christenson has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. Each of the General Partner and Dr. Christenson disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner or Dr. Christenson is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Row 2 · 2020-06-30 · Conversion · Acquired 1,069,902 · Balance 3,567,247 F3: Represents Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemable into Class B Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class B Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis. F2: The securities are directly held by HealthCap VII, L.P. ("HCLP"). HealthCap VII GP SA ("HCSA") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. Johan Christenson has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. Each of the General Partner and Dr. Christenson disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner or Dr. Christenson is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Row 3 · 2020-06-30 · Purchase · Acquired 240,000 · Balance 3,807,247 F2: The securities are directly held by HealthCap VII, L.P. ("HCLP"). HealthCap VII GP SA ("HCSA") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. Johan Christenson has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. Each of the General Partner and Dr. Christenson disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner or Dr. Christenson is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
Class A Preferred Exchangeable SharesSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2020-06-30 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-06-30 · Conversion · Disposed 13,333,333 · Balance 0 F1: Represents Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemable into Class A Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class A Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis. F2: The securities are directly held by HealthCap VII, L.P. ("HCLP"). HealthCap VII GP SA ("HCSA") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. Johan Christenson has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. Each of the General Partner and Dr. Christenson disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner or Dr. Christenson is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
Class B Preferred Exchangeable SharesSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2020-06-30 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-06-30 · Conversion · Disposed 5,712,216 · Balance 0 F3: Represents Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemable into Class B Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class B Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis. F2: The securities are directly held by HealthCap VII, L.P. ("HCLP"). HealthCap VII GP SA ("HCSA") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. Johan Christenson has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. Each of the General Partner and Dr. Christenson disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner or Dr. Christenson is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

Filing footnotes · ownership attribution and instrument terms

F1: Represents Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemable into Class A Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class A Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis.

F2: The securities are directly held by HealthCap VII, L.P. ("HCLP"). HealthCap VII GP SA ("HCSA") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. Johan Christenson has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. Each of the General Partner and Dr. Christenson disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner or Dr. Christenson is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

F3: Represents Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemable into Class B Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class B Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 30, 2020 Filed Jul 2, 2020 16:02 UTC	Fusion Pharmaceuticals Inc. FUSN · Entity 11851	ConversionClass B Preferred Exchangeable Shares · Derivative	5,712,216	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-018256 · doc4.xml · derivative · entry 5 HealthCap VII, L.P. · CIK 0001645161 · 10% owner HealthCap VII GP S.A. · CIK 0001790047 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Shares · 1,069,902 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Represents Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemable into Class B Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class B Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis. F3 · derivative.exercise_price: Represents Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemable into Class B Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class B Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis. F3 · price: Represents Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemable into Class B Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class B Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis. F3 · derivative.exercise_date: Represents Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemable into Class B Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class B Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis. F3 · derivative.expiration_date: Represents Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemable into Class B Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class B Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis. F2 · ownership.nature: The securities are directly held by HealthCap VII, L.P. ("HCLP"). HealthCap VII GP SA ("HCSA") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. Johan Christenson has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. Each of the General Partner and Dr. Christenson disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner or Dr. Christenson is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document
June 30, 2020 Filed Jul 2, 2020 16:02 UTC	Fusion Pharmaceuticals Inc. FUSN · Entity 11851	ConversionClass A Preferred Exchangeable Shares · Derivative	13,333,333	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-018256 · doc4.xml · derivative · entry 4 HealthCap VII, L.P. · CIK 0001645161 · 10% owner HealthCap VII GP S.A. · CIK 0001790047 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Shares · 2,497,345 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemable into Class A Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class A Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis. F1 · derivative.exercise_price: Represents Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemable into Class A Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class A Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis. F1 · price: Represents Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemable into Class A Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class A Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis. F1 · derivative.exercise_date: Represents Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemable into Class A Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class A Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis. F1 · derivative.expiration_date: Represents Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemable into Class A Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class A Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis. F2 · ownership.nature: The securities are directly held by HealthCap VII, L.P. ("HCLP"). HealthCap VII GP SA ("HCSA") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. Johan Christenson has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. Each of the General Partner and Dr. Christenson disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner or Dr. Christenson is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document
June 30, 2020 Filed Jul 2, 2020 16:02 UTC	Fusion Pharmaceuticals Inc. FUSN · Entity 11851	PurchaseCommon Shares	240,000	$17.00	$4,080,000.00	Disclosure SEC source: 0000899243-20-018256 · doc4.xml · nonDerivative · entry 3 HealthCap VII, L.P. · CIK 0001645161 · 10% owner HealthCap VII GP S.A. · CIK 0001790047 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,807,247 F2 · ownership.nature: The securities are directly held by HealthCap VII, L.P. ("HCLP"). HealthCap VII GP SA ("HCSA") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. Johan Christenson has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. Each of the General Partner and Dr. Christenson disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner or Dr. Christenson is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document
June 30, 2020 Filed Jul 2, 2020 16:02 UTC	Fusion Pharmaceuticals Inc. FUSN · Entity 11851	ConversionCommon Shares	1,069,902	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-018256 · doc4.xml · nonDerivative · entry 2 HealthCap VII, L.P. · CIK 0001645161 · 10% owner HealthCap VII GP S.A. · CIK 0001790047 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,567,247 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Represents Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemable into Class B Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class B Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class B Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis. F2 · ownership.nature: The securities are directly held by HealthCap VII, L.P. ("HCLP"). HealthCap VII GP SA ("HCSA") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. Johan Christenson has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. Each of the General Partner and Dr. Christenson disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner or Dr. Christenson is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document
June 30, 2020 Filed Jul 2, 2020 16:02 UTC	Fusion Pharmaceuticals Inc. FUSN · Entity 11851	ConversionCommon Shares	2,497,345	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-018256 · doc4.xml · nonDerivative · entry 1 HealthCap VII, L.P. · CIK 0001645161 · 10% owner HealthCap VII GP S.A. · CIK 0001790047 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,497,345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited. The Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemable into Class A Preferred Shares of the Issuer. Upon the closing of the Issuer's initial public offering, the Class A Preferred Exchangeable Shares of Fusion Pharmaceuticals (Ireland) Limited were redeemed into Class A Preferred Shares of the Issuer on a one-for-one basis, which subsequently converted into Common Shares of the Issuer on a one-for-5.339 basis. F2 · ownership.nature: The securities are directly held by HealthCap VII, L.P. ("HCLP"). HealthCap VII GP SA ("HCSA") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. Johan Christenson has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. Each of the General Partner and Dr. Christenson disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner or Dr. Christenson is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document
October 07, 2019 Filed Oct 7, 2019 19:53 UTC	Aprea Therapeutics, Inc. APRE · Entity 7948	ConversionSeries C Convertible Preferred Stock · Derivative	427,496	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-025205 · doc4.xml · derivative · entry 5 HealthCap VII, L.P. · CIK 0001645161 · 10% owner HealthCap VII GP S.A. · CIK 0001790047 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 427,496 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior the closing of the Issuer's initial public offering the shares of preferred stock automatically converted into shares of the common stock. Each share of preferred stock was convertible into shares of common stock at any time at the option of the holder and had no expiration date. F1 · price: Immediately prior the closing of the Issuer's initial public offering the shares of preferred stock automatically converted into shares of the common stock. Each share of preferred stock was convertible into shares of common stock at any time at the option of the holder and had no expiration date. F1 · derivative.exercise_date: Immediately prior the closing of the Issuer's initial public offering the shares of preferred stock automatically converted into shares of the common stock. Each share of preferred stock was convertible into shares of common stock at any time at the option of the holder and had no expiration date. F1 · derivative.expiration_date: Immediately prior the closing of the Issuer's initial public offering the shares of preferred stock automatically converted into shares of the common stock. Each share of preferred stock was convertible into shares of common stock at any time at the option of the holder and had no expiration date. F2 · ownership.nature: The securities are directly held by HealthCap VII L.P. (the "Fund"). HealthCap VII GP S.A. (the "General Partner") is the sole general partner of the Fund. The General Partner disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document
October 07, 2019 Filed Oct 7, 2019 19:53 UTC	Aprea Therapeutics, Inc. APRE · Entity 7948	ConversionSeries B Convertible Preferred Stock · Derivative	1,661,382	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-025205 · doc4.xml · derivative · entry 4 HealthCap VII, L.P. · CIK 0001645161 · 10% owner HealthCap VII GP S.A. · CIK 0001790047 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,661,382 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior the closing of the Issuer's initial public offering the shares of preferred stock automatically converted into shares of the common stock. Each share of preferred stock was convertible into shares of common stock at any time at the option of the holder and had no expiration date. F1 · price: Immediately prior the closing of the Issuer's initial public offering the shares of preferred stock automatically converted into shares of the common stock. Each share of preferred stock was convertible into shares of common stock at any time at the option of the holder and had no expiration date. F1 · derivative.exercise_date: Immediately prior the closing of the Issuer's initial public offering the shares of preferred stock automatically converted into shares of the common stock. Each share of preferred stock was convertible into shares of common stock at any time at the option of the holder and had no expiration date. F1 · derivative.expiration_date: Immediately prior the closing of the Issuer's initial public offering the shares of preferred stock automatically converted into shares of the common stock. Each share of preferred stock was convertible into shares of common stock at any time at the option of the holder and had no expiration date. F2 · ownership.nature: The securities are directly held by HealthCap VII L.P. (the "Fund"). HealthCap VII GP S.A. (the "General Partner") is the sole general partner of the Fund. The General Partner disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document
October 07, 2019 Filed Oct 7, 2019 19:53 UTC	Aprea Therapeutics, Inc. APRE · Entity 7948	PurchaseCommon Stock	266,667	$15.00	$4,000,005.00	Disclosure SEC source: 0000899243-19-025205 · doc4.xml · nonDerivative · entry 3 HealthCap VII, L.P. · CIK 0001645161 · 10% owner HealthCap VII GP S.A. · CIK 0001790047 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,366,104 F2 · ownership.nature: The securities are directly held by HealthCap VII L.P. (the "Fund"). HealthCap VII GP S.A. (the "General Partner") is the sole general partner of the Fund. The General Partner disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document
October 07, 2019 Filed Oct 7, 2019 19:53 UTC	Aprea Therapeutics, Inc. APRE · Entity 7948	ConversionCommon Stock	427,496	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-025205 · doc4.xml · nonDerivative · entry 2 HealthCap VII, L.P. · CIK 0001645161 · 10% owner HealthCap VII GP S.A. · CIK 0001790047 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,099,437 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Immediately prior the closing of the Issuer's initial public offering the shares of preferred stock automatically converted into shares of the common stock. Each share of preferred stock was convertible into shares of common stock at any time at the option of the holder and had no expiration date. F2 · ownership.nature: The securities are directly held by HealthCap VII L.P. (the "Fund"). HealthCap VII GP S.A. (the "General Partner") is the sole general partner of the Fund. The General Partner disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document
October 07, 2019 Filed Oct 7, 2019 19:53 UTC	Aprea Therapeutics, Inc. APRE · Entity 7948	ConversionCommon Stock	1,661,382	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-025205 · doc4.xml · nonDerivative · entry 1 HealthCap VII, L.P. · CIK 0001645161 · 10% owner HealthCap VII GP S.A. · CIK 0001790047 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,671,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Immediately prior the closing of the Issuer's initial public offering the shares of preferred stock automatically converted into shares of the common stock. Each share of preferred stock was convertible into shares of common stock at any time at the option of the holder and had no expiration date. F2 · ownership.nature: The securities are directly held by HealthCap VII L.P. (the "Fund"). HealthCap VII GP S.A. (the "General Partner") is the sole general partner of the Fund. The General Partner disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of its indirect pecuniary interest therein, and this report shall not be deemed an admission that the General Partner is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.